Skip Navigation
Print This Page
Share this page: More

Search Results

A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (CO-338-017)
Protocol Number:
Phase II
Deborah Armstrong
- To determine the efficacy of Rucaparib - To evaluate progression free survival
- Recurrent platinum sensitive ovarian, fallopian tube or primary peritoneal cancer - Platinum sensitive disease is defined as progression greater than 6 months after last dose of platinum agent - must have a biopsy prior to starting on study - measurable disease - Good lab results and performace status
Treatment is with an oral drug (Rucaparib) that is taken twice a day. It is given on an outpatient basis. You will be given a 28 day supply. There are additional lab and scan requirements.
Last Update
09/16/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer